LENZ Therapeutics Inc. Common Stock (LENZ)

FairStock Score: 32/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham investor, I begin with owner earnings and a margin of safety. LENZ is a commercial-stage biotech with 152 employees, focused on presbyopia therapies VIZZ and LNZ101. Revenue is emerging: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $5.5M, up from $5.0M in fiscal Q2 2025, the quarter ended 2025-06-30. But the losses are heavy. Net loss was $31.9M in fiscal Q2 2026 and $41.5M in fiscal Q1 2026, the quarter ended 2026-03-31. In fiscal year 2025, the year ended 2025-12-31, revenue was $19.1M and net loss was $82.1M; fiscal year 2024, ended 2024-12-31, had no reported revenue and a $49.8M net loss. Free cash flow is -$114.4M trailing twelve months, a -107.1% FCF yield, per FairStock, against a $106.8M market cap at the 2026-10-13 close. The balance sheet has no debt (D/E 0.00), which helps, but cash burn is the dominant fact. On valuation, FairStock shows P/B 0.49 and P/E -0.82 at that close, ROE -59.21%, ROCE -37.36%, Piotroski 5/9, Altman Z 2.56, a FairStock score of 32/100, and no Lynch category because of losses in each of the last four years. A drug candidate can become a wide-moat business, but today there is no proven durable pricing power. The stock price is far below its 52-week high of $42.98, but cheapness without earning power is speculation. I would need evidence of commercial traction and a credible path to profits before calling this a margin-of-safety bargain.

In plain English: LENZ Therapeutics is a small drug company working on eye treatments to improve near vision in adults. It is not yet profitable: in fiscal Q2 2026, the quarter ended 2026-06-30, it had $5.5 million of revenue and a $31.9 million net loss, and over the last year it used $114.4 million of cash. The share price looks low compared with its accounting value, but the business is still losing money, so the price is only cheap if the treatments eventually succeed.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer